New York is currently home to 4451 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criter... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/10/2025
Locations: Dent Neurologic Institute - Amherst- Site Number : 8400129, Amherst, New York
Conditions: Multiple Sclerosis
A Safety Study of SGN-35T in Adults With Advanced Cancers
Recruiting
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infections. There are several types of lymphoma. This study will enroll people who have lymphoma, such as classical Hodgkin lymphoma, peripheral T-cell lymphoma including systemic anaplastic large cell lymphoma, diffuse large B-cell lymphoma, or types of primary cutaneous lymphoma. This clinical trial uses a drug called SGN-35T. The study drug is in testing and has not been approved for sale... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
SilverCloud as a School-Based Intervention for Vulnerable Youth
Recruiting
The goal of this study is to test the efficacy and feasibility of a clinician-guided, app-based cognitive behavioral therapy (CBT) program, SilverCloud, as a school-based mental health intervention for vulnerable youth. An open trial of SilverCloud will be conducted to determine preliminary efficacy in this sample and inform program refinements by collecting outcome self-report assessments and conducting interviews on feasibility and acceptability. After the program and its implementation strate... Read More
Gender:
ALL
Ages:
Between 13 years and 22 years
Trial Updated:
03/10/2025
Locations: NYU Langone Health, Brooklyn, New York
Conditions: Depression, Anxiety
GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery
Recruiting
This is a pre-market, prospective, randomized (1:1), multicenter, pivotal clinical investigation. The purpose of this investigation is to determine the clinical performance of GATT-Patch as compared with SURGICEL® Original for the management of minimal, mild, or moderate bleeding during minimally invasive liver and gallbladder surgery.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/10/2025
Locations: Weill-Cornell, New York, New York
Conditions: Intraoperative Bleeding, Liver Diseases, Gallbladder Diseases, Hemorrhage, Surgical
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Recruiting
The main purpose of the study is to evaluate the safety and tolerability of HRO761 and identify the recommended dose(s), i.e., the optimal safe and active dose of HRO761 alone or in combination with pembrolizumab or irinotecan that can be given to patients who have cancers with specific molecular alterations called MSIhi (Microsatellite Instability-high) or dMMR (Mismatch Repair Deficient) that might work best to treat these specific cancer types and to understand how well HRO761 is able to trea... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/10/2025
Locations: Memorial Sloan Kettering, New York, New York
Conditions: MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression
Recruiting
This project will evaluate a telemedicine-delivered, Unified Protocol for Cognitive-Behavioral Therapy (UP-CBT) enhanced with continuous glucose monitor (CGM) review to target anxiety and depressive symptoms and glycemic control in adults with type 1 diabetes.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/10/2025
Locations: Albert Einstein College of Medicine, Bronx, New York
Conditions: Diabetes, Type 1 Diabetes
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma (ARGSARC)
Recruiting
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/10/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Soft Tissue Sarcoma
A Study Evaluating the Effects of GLPG3667 Given As Oral Treatment for Up to 24 Weeks in Adults with Dermatomyositis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered GLPG3667 once daily for 24 weeks in adult participants with dermatomyositis (DM), followed by an open-label extension (OLE) period until Week 48.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/10/2025
Locations: Northwell Health, LLC PRIME, Lake Success, New York
Conditions: Dermatomyositis
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Recruiting
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason and safety and tolerability in subjects wit... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
03/10/2025
Locations: The Feinstein Institutes for Medical Research - BRANY - PPDS, Manhasset, New York
Conditions: Psychosis Associated With Alzheimer's Disease
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
Recruiting
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.
Gender:
MALE
Ages:
Between 18 years and 130 years
Trial Updated:
03/10/2025
Locations: Research Site, Syracuse, New York
Conditions: Metastatic Prostate Cancer
LMN-201 for Prevention of C. Difficile Infection Recurrence
Recruiting
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Clostridioides Difficile Infection